

**Comparison of COVID-19 outcomes among shielded and non-shielded populations:  
A general population cohort study of 1.3 million**

Bhautesh D Jani<sup>†</sup>, Frederick K Ho<sup>†</sup>, David J Lowe, Jamie P Traynor, Sean MacBride-Stewart, Patrick B Mark, Frances S Mair, Jill P Pell\*

<sup>†</sup>Joint-first author

Bhautesh D Jani PhD  
Clinical Senior Lecturer in General Practice and Primary Care  
Institute of Health and Wellbeing, University of Glasgow  
Glasgow G12 9LX, UK  
[Bhautesh.jani@glasgow.ac.uk](mailto:Bhautesh.jani@glasgow.ac.uk)

Frederick K Ho PhD  
Research Associate  
Institute of Health and Wellbeing, University of Glasgow  
Glasgow, G12 8RZ, UK  
[Frederick.Ho@glasgow.ac.uk](mailto:Frederick.Ho@glasgow.ac.uk)

David J Lowe MSc  
Consultant in Emergency Medicine  
Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde  
Glasgow, G52 4TF, UK  
[David.lowe@nhs.net](mailto:David.lowe@nhs.net)

Jamie P Traynor MD  
Consultant Nephrologist  
Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde  
Glasgow, G52 4TF, UK  
[Jamie.traynor@ggc.scot.nhs.uk](mailto:Jamie.traynor@ggc.scot.nhs.uk)

Sean MacBride-Stewart PhD  
Lead Pharmacist (Medicines Management Resources)  
Pharmacy Services, NHS Greater Glasgow and Clyde  
Glasgow, G76 7AT, UK  
[Sean.MacBride-Stewart@ggc.scot.nhs.uk](mailto:Sean.MacBride-Stewart@ggc.scot.nhs.uk)

Patrick B Mark PhD  
Professor of Nephrology  
Institute of Cardiovascular and Medical Sciences, University of Glasgow  
Glasgow, G12 8TA, UK  
[Patrick.Mark@glasgow.ac.uk](mailto:Patrick.Mark@glasgow.ac.uk)

Frances S Mair MD  
Norie Miller Professor of General Practice  
Institute of Health and Wellbeing, University of Glasgow  
Glasgow G12 9LX, UK

[Frances.mair@glasgow.ac.uk](mailto:Frances.mair@glasgow.ac.uk)

Jill P Pell MD

Henry Mechan Professor of Public Health

Institute of Health and Wellbeing, University of Glasgow

Glasgow, G12 8RZ, UK

[Jill.pell@glasgow.ac.uk](mailto:Jill.pell@glasgow.ac.uk)

**\*Address for correspondence:**

Professor Jill Pell

Director of the Institute of Health and Wellbeing

University of Glasgow

1 Lilybank Gardens

Glasgow G12 8RZ

United Kingdom

[Jill.pell@glasgow.ac.uk](mailto:Jill.pell@glasgow.ac.uk)

**Supplementary Table 1.** Vulnerable Patient List in UK


<b>High Risk</b>	<b>Moderate Risk</b>
<p>Severe respiratory disease:</p> <ul style="list-style-type: none"> <li>• severe COPD</li> <li>• severe asthma (high-dose steroids)</li> <li>• cystic fibrosis</li> </ul> <p>Specific cancers:</p> <ul style="list-style-type: none"> <li>• Lung cancer plus radical radiotherapy or active chemotherapy</li> <li>• Blood or bone marrow cancers</li> <li>• Bone marrow or stem cell transplant           <ul style="list-style-type: none"> <li>◦ in last 6 months, or</li> <li>◦ still taking immunosuppressants</li> </ul> </li> <li>• immunotherapy or continuing antibody treatment</li> <li>• protein kinase inhibitors or PARP inhibitors</li> </ul> <p>Pregnant with significant heart disease</p> <p>Immunosuppressive therapy</p> <p>Solid organ transplant</p> <p>Relevant rare diseases and inborn errors of metabolism (e.g. SCID, homozygous sickle cell)</p> <p>Renal dialysis</p>	<p>Chronic respiratory disease:</p> <ul style="list-style-type: none"> <li>• COPD</li> <li>• asthma</li> <li>• emphysema</li> <li>• bronchitis</li> </ul> <p>Other chronic conditions</p> <ul style="list-style-type: none"> <li>• heart disease/hypertension</li> <li>• diabetes</li> <li>• kidney disease</li> <li>• liver disease</li> <li>• neurological conditions</li> </ul> <p>Pregnant</p> <p>Weakened immune system due to:</p> <ul style="list-style-type: none"> <li>• Medical condition</li> <li>• Medication (e.g. oral steroids, chemotherapy)</li> </ul> <p>BMI <math>\geq 40 \text{ kg/m}^2</math></p> <p><math>\geq 70</math> years of age</p>

**Supplementary Table 2.** Population attributable fractions for risk categories and risk criteria and COVID-19 outcomes

	Confirmed COVID-19		COVID-19 hospitalisation		COVID-19 ICU admission		COVID-19 Death	
	%	95% CI	%	95% CI	%	95% CI	%	95% CI
<b>Moderate</b>								
Overall	42.06	41.49-42.64	53.28	52.78-53.78	22.96	17.70-29.09	75.30	75.09-75.51
Chronic respiratory disease	3.56	3.29-3.83	4.84	4.58-5.09	0.99	-2.93-5.28	2.23	2.00-2.50
Heart disease	4.83	4.73-4.94	5.97	5.86-6.08	1.92	0.27-3.55	6.19	6.10-6.28
Hypertension	5.33	5.19-5.45	7.06	6.93-7.18	10.82	9.41-12.11	4.99	4.90-5.09
Diabetes	10.39	10.17-10.58	12.96	12.77-13.15	9.87	7.09-12.63	12.00	11.82-12.18
Weakened immune system	0.15	0.13-0.16	0.26	0.24-0.28	-	-	0.34	0.32-0.36
≥70 years of age	17.81	17.62-18.01	22.19	21.98-22.43	-	-	49.55	49.18-49.94
<b>High</b>								
Overall	7.62	7.45-7.79	12.70	12.46-12.90	2.69	1.44-4.10	13.22	13.02-13.39
Severe respiratory disease	3.35	3.24-3.46	6.08	5.97-6.20	-	-	7.01	6.89-7.11
Specific cancers	0.88	0.84-0.92	1.42	1.37-1.48	-	-	1.31	1.27-1.36
Immunosuppressive therapy	1.41	1.36-1.47	2.43	2.36-2.51	-	-	2.05	1.99-2.11
Solid organ transplant	0.39	0.37-0.42	0.73	0.68-0.77	-	-	0.57	0.54-0.60
Rare diseases and IEM	0.84	0.79-0.88	1.17	1.11-1.23	-	-	1.72	1.64-1.81
Renal dialysis	0.75	0.68-0.82	0.86	0.78-0.94	-	-	0.55	0.50-0.61

CI confidence interval; IEM inborn errors of metabolism

**Supplementary Figure 1.** Cumulative population attributable fractions (lines) and population prevalence (bars) for individual risk criteria



Brown – shielded

Pale orange – moderate-risk